Fierce Pharma

JANUARY 8, 2024

Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. Morgan Healthcare Conference. |

Prospecting 224

Prospecting Biopharma Pharma Healthcare 224

MedCity News

JULY 1, 2024

The post Eli Lilly Puts $1B on the Line to Expand its Cancer Radiopharmaceuticals Prospects appeared first on MedCity News. The clinical-stage startup, a Crinetics Pharmaceuticals spinout, develops radiopharmaceuticals that target GPCRs overexpressed by solid tumors.

Prospecting 195

Prospecting Pharmaceutical Biopharma Pharma 195

MedCity News

MAY 14, 2024

The post AbbVie Expands Psychiatric Drug Prospects, Inking R&D Pact With Neuroscience Startup appeared first on MedCity News. AbbVie’s alliance with Gilgamesh Pharmaceuticals is pursuing next-generation psychiatric medications.

Prospecting 182

Prospecting Side effects Pharmaceutical Medical 182

MedCity News

OCTOBER 27, 2022

GSK drug otilimab failed a Phase 3 test in rheumatoid arthritis. Though the antibody drug met the main goal in two other pivotal studies, GSK said the limited efficacy in the third study means the company will not seek regulatory approval.

Prospecting 264

Prospecting Biopharma Pharma 264

MedCity News

SEPTEMBER 21, 2023

Seven months after Travere Therapeutics’ flagship drug received accelerated FDA approval in a rare kidney disease, the molecule has fallen short of the key goal of its confirmatory test. It’s the small molecule’s second Phase 3 failure this year.

Prospecting 298

Prospecting FDA Biopharma Pharma 298

European Pharmaceutical Review

DECEMBER 30, 2023

The past 12 months has seen significant growth in global mergers and acquisitions (M&A) within the biopharma sector. This activity is expected to continue in 2024, with increasing need for biopharma to access innovation through collaboration and dealmaking to offset looming patent challenges. “In

Biopharma 105

Biopharma Marketing Prospecting Pharmaceutical 105

MedCity News

NOVEMBER 22, 2023

With financing prospects dim and no one willing to take on its assets, Evelo is dissolving its business. Evelo Biosciences’ vision of using microbes to engage the gut and modulate immune responses remains unrealized.

Prospecting 310

Prospecting Biopharma Pharma 310

MedCity News

APRIL 17, 2023

The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years. Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders.

Medicine 292

Medicine Prospecting Leads Biopharma 292

MedCity News

JUNE 29, 2023

Eli Lilly is expanding its diabetes prospects by acquiring cell therapy developer Sigilon Therapeutics. The two companies are already partners in the development of a type 1 diabetes cell therapy currently in preclinical development.

Prospecting 258

Prospecting Biopharma Pharma 258

MedCity News

MARCH 19, 2023

Prospective buyers can pick up Pear’s FDA-cleared products for substance use disorder, opioid use disorder, and insomnia. Pear Therapeutics isn’t meeting the commercialization goals for its prescription digital therapeutics, so it’s now seeking strategic alternatives for the business.

Prescription 246

Prescription Prospecting FDA Biopharma 246

PM360

FEBRUARY 1, 2024

Embarking on the journey from product development to market success in the biopharma industry is no small feat. According to a McKinsey report , a startling 40% of biopharma products fail to meet their sales forecasts within the initial two years, prompting a critical reassessment of strategies for product launches.

Biopharma 59

Biopharma Competition Prescription Marketing 59

Zymewire

DECEMBER 22, 2023

As we all unwind for the holidays, we’re taking a break from the realm of prospecting in biopharma to highlight a group of folks who have woven the spirit of giving into the fabric of clinical research.

Biopharma 52

Biopharma Prospecting 52

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. Evaluate’s VC data show quarter-over-quarter drops in the number of biopharma companies raising private cash and in the amount of money raised.

Biopharma 111

Biopharma Pharma Marketing Management 111

Pharmaceutical Technology

SEPTEMBER 13, 2022

The company provides strategic assistance and regulatory support to biopharma firms across the lifecycle of the product. The PharmaLex takeover will build upon the current European presence of AmerisourceBergen in pharmaceutical supply and biopharma manufacturer services expertise.

Biopharma 52

Biopharma Manufacturing Pharmaceutical manufacturing Marketing 52

Medico Reach

AUGUST 1, 2022

Whether you are a start-up looking for investment or are interested in working in venture capital (VC), the worldwide biopharma and MedTech industries are growing. In 2022, over $14 billion was funded in biopharma setup globally, and 37 major IPOs of VC-backed biotech company businesses raised a combined $4.2 CEO : Samuel Isaly.

Biopharma 52

Biopharma Healthcare Healthcare Engineering 52

pharmaphorum

DECEMBER 28, 2022

billion buyout of Principia Biopharma. While the partial hold may simply be a hiccup for InnoCare and Biogen’s programme, it does undermine prospects for orelabrutinib, which is one of several oral BTK inhibitors being developed for MS and other autoimmune diseases.

FDA 75

FDA Side effects Biopharma Prospecting 75

The Marketing Advantage

FEBRUARY 26, 2024

Despite these challenges, the sales force is one of the most important tools a biopharma company has in driving disease awareness and reaching these too often underserved patients, requiring effective sales compensation planning and goal setting. So then how should goals be set for rare disease products?

Sales 52

Sales Prospecting Consulting Biopharma 52

pharmaphorum

DECEMBER 16, 2022

Last month, Astellas reported similar results in its SPOTLIGHT trial, which had largely the same design as GLOW, but replaced CAPOX with another chemo regimen called mFOLFOX6 , and with two positive phase 3 trials in the bag the drugmaker can now turn its attention to regulatory filings and the prospect of being first to market with a claudin 18.2

Leads 59

Leads Biopharma Prospecting Patients 59

Pharmaceutical Technology

MAY 22, 2023

The result was a plethora of patient infringement lawsuits , with several cases being filed that included Moderna, Pfizer/BioNTech, Alnylam Pharmaceuticals, Arbutus Biopharma, and Genevant Sciences on different sides of the court. With the emergence of vaccines came accusations of technology encroachment amongst biotech companies.

Biopharma 116

Biopharma Prospecting Competition Pharmaceutical 116

PM360

APRIL 7, 2023

Biopharma should pay special attention to this. Biopharma companies that bring patients together in-person can create a sense of belonging and support that is often missing in the digital realm. Social Connections and Mortality from all Causes and from Cardiovascular Disease: Prospective Evidence from Eastern Finland.”

Biopharma 52

Biopharma Patients Specialization Networking 52

European Pharmaceutical Review

JULY 20, 2023

AAV development for cell and gene therapy The topic of product quality was introduced in a panel discussion on AAVs in gene therapy, which saw speakers address the obstacles and prospects concerning IND application through to commercialisation. In a separate dialogue, Dr Baghirzade agreed that the industry “is still evolving”.

Consulting 74

Consulting Manufacturing Side effects Safety 74

The Marketing Advantage

JULY 10, 2023

We at The Marketing Advantage have been designing call plans based on sales, opportunity, potential, maintenance and growth for the biopharma industry for over 30 years. However, what we find is that in about three months, representatives who received only 5 or 6 super prospects wish that they had gotten 8.

Sales 40

Sales Consulting Specialization Prospecting 40

PM360

OCTOBER 18, 2024

Given that you have led big pharma (J&J) and smaller firms (Theravance and now FogPharma), what are the career prospects and trajectory for mid-career / newly graduating students wanting to enter this vertical? What would be your advice for prospective professionals seeking a career in big pharma versus smaller firms, including startups?

Medicine 52

Medicine Education Prospecting Networking 52

PM360

APRIL 22, 2024

With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.

Education 59

Education Physicians Healthcare Healthcare 59

Clarivate

FEBRUARY 28, 2023

“A Hospital-Based Five-Year Prospective Study on the Prevalence of Leber’s Hereditary Optic Neuropathy with Genetic Confirmation.” . “Leber Hereditary Optic Neuropathy: Case Report and Literature Review.” ” Cureus; V.12; 4; 4/20/2020; DOI:10.7759/cureus.7745 7745 [4] Gowri P et al.

Patients 98

Patients Prescription Pharmacology Healthcare 98

Pharmaceutical Technology

JUNE 20, 2023

At $48 a share for the South San Francisco,California-based biopharma, Lilly is paying a 40% premium on top of the 30-day average trading price. GlobalData is the parent company of Pharmaceutical Technology DICE’s novel oral therapeutic candidates positioned it as an attractive prospect for acquisition.

Prospecting 52

Prospecting Competition Biopharma Marketing 52

Pharmaceutical Technology

JUNE 16, 2023

Synthetic biology biopharma Biostar Pharma announced is ready to advance its utidelone injectable (UTD1) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), following approval from the US Food and Drug Administration (FDA) for the study.

FDA 52

FDA Food and Drug Administration Patients Marketing 52

Pharmaceutical Technology

MAY 3, 2023

The proposed facility would play a vital role in fulfilling demand in the Asia Pacific region while representing an important hub for further biopharma industry development in South Korea.” We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Government 52

Government Electronics Biopharma Prospecting 52

Pharmaceutical Technology

JANUARY 15, 2023

Baxter Biopharma Solutions, Fareva SA, BSP Pharmaceuticals SpA, and Takeda Pharmaceuticals are manufacturing the parenteral portion of the ADC. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Manufacturing 52

Manufacturing Pharmaceutical FDA Pharma 52

Pharmaceutical Technology

MARCH 31, 2023

In the panel, Melanie Senior, a biopharma reporter at Nature Biotech also pointed out reimbursement issues for obesity drugs. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Training 52

Training Competition Biopharma Prospecting 52

Clarivate

DECEMBER 6, 2022

In July 2022, ChristianaCare acquired the shuttered Jennersville Hospital from Tower Health, but plans to purchase four-hospital Crozer Health from for-profit Prospect Medical Holdings fell through in September 2022.

Networking 52

Networking Healthcare Healthcare Competition 52

Zymewire

FEBRUARY 8, 2024

Skip to a topic Axonis' journey and purpose The impact of the economic client on emerging biopharma The place of Artificial Intelligence in drug development & discovery Working with NASA Relationships with CROs, CDMOs, and other service providers What made you want to start Axonis? sending neurons to space.

Competition 52

Competition Leads Patients Marketing 52

Pharmaceutical Technology

APRIL 16, 2023

This is an exciting prospect: oncology, and immuno-therapy in particular, is a driving force behind biotech R&D, with new cancer therapies and molecules accounting for nearly 40% 1 of the industry’s development pipeline. SHL Medical’s Maggie 5.0

Medical 52

Medical Medicine Patients Manufacturing 52

European Pharmaceutical Review

OCTOBER 27, 2022

The report’s authors identified that nearly 36 percent of biopharma companies will be increasing their spending on outsourced R&D or biomanufacturing over the next 12 months. Average budgets for outsourcing at individual facilities also remain relatively steady, growing by a weighted average increase of 12.8 percent in 2022.

Biopharma 98

Biopharma Manufacturing Pharmacology Marketing 98

PM360

NOVEMBER 12, 2023

While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., market, emerging markets present great opportunities for biotech and pharmaceutical companies.

Marketing 59

Marketing Biopharma Government Pharma 59

Clarivate

MAY 8, 2024

As companies face the prospect of major revenue challenges over the next few years, securing inorganic growth through strategic alliances is increasingly attractive. As a result, 2023 saw an upsurge in merger and acquisition (M&A) and deal activity.

Pharma 59

Pharma Biopharma Prospecting Competition 59

Clarivate

DECEMBER 14, 2023

A long winter for biotech financing: Capital scarcity is likely to continue as prospective investors and partners remain cautious, due to rising interest rates and concerns around externalities such as government initiatives to contain healthcare costs and global geopolitical conflicts.

Pharma 111

Pharma Government Pharmacology Healthcare 111